Showing 1471-1480 of 1665 results for "".
- New Plasma Proteins Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/new-plasma-proteins-linked-atopic-dermatitis-risk/2467771/New research has identified eight plasma proteins associated with atopic dermatitis (AD), potentially opening new avenues for treatment. Publishing in the Archives of Dermatological Research, the study authors used summary-data-based Mendelian Randomization (SMR) and evaluated dat
- Weekly Cendakimab Dosing Effective in Reducing AD Severityhttps://practicaldermatology.com/news/weekly-cendakimab-dosing-effective-reducing-ad-severity/2467489/New research shows that cendakimab is safe and efficacious at certain dosing levels over a 16-week study period in patients with moderate-to-severe atopic dermatitis (AD). The study authors for the phase 2 trial included 221 adult patients with moderate-to-severe AD from the United States
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho
- Survey Reveals Variation in Hyaluronidase Use in Aesthetic Practicehttps://practicaldermatology.com/news/survey-reveals-variation-hyaluronidase-use-aesthetic-practice/2466937/New research suggests a need for guidelines around the storage and dosing for hyaluronidase (HYAL) when using hyaluronic acid (HA) fillers. "Hyaluronic acids continue to be the fillers of choice worldwide and their popularity is growing," the authors wrote in Aesthetic Surgery Journa
- Study: Frequent Dermatologist Visits Boost Melanoma Survival Rateshttps://practicaldermatology.com/news/study-frequent-dermatologist-visits-boost-melanoma-survival-rates/2463097/New research suggests that patients with melanoma who engage in more frequent visits to the dermatologist show higher rates of survival. "Guidelines recommend that patients with melanoma undergo dermatologic examination at least annually," the authors wrote in the Journal of the American
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support
- Study: Markers Reveal New Diagnostic Paths in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/study-markers-reveal-new-diagnostic-paths-chronic-spontaneous-urticaria/2462978/A recent study highlighted new diagnostic markers and pathways in chronic spontaneous urticaria (CSU). Researchers publishing in the International Journal of Dermatology included 90 CSU patients and 90 healthy individuals in the analysis. The authors then analyzed markers from di
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- Oral and Topical Minoxidil for Male Androgenetic Alopecia Show Similar Efficacy: Analysishttps://practicaldermatology.com/news/oral-and-topical-minoxidil-male-androgenetic-alopecia-similar-efficacy-analysis/2462791/Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male androgenetic alopecia (AGA). The authors conducted the double-blind, placebo-controlled randomized clinical trial in Brazil aiming to evalua